Want to see FR:GNFT full AI Analyst Report?
GNFT Stock Chart & Stats
€14.30
€0.20(1.49%)
At close: 4:00 PM EDT
€14.30
€0.20(1.49%)
Day’s Range― - ―
52-Week Range€3.05 - €15.48
Previous CloseN/A
Volume267.52K
Average Volume (3M)265.55K
Market Cap
€519.94M
Enterprise Value€312.09
Total Cash (Recent Filing)€101.09M
Total Debt (Recent Filing)€150.69M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Sep 29, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding50,099,620
10 Day Avg. Volume336,511
30 Day Avg. Volume265,545
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-11.11
Price to Sales (P/S)4.01
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.00Price Target Upside4.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.3
Revenue Forecast (FY)€86.71M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp 2025 revenue rebound shows that Genfit can generate substantial top-line growth from its clinical and diagnostic activities. If supported by further pipeline progress or transactions, this provides a larger base for future partnerships, milestones, and potential commercialization.
Specialized Pipeline FocusA focused position in metabolic and liver diseases gives Genfit a clearly defined scientific and commercial domain. Its work on non-invasive diagnostics, biomarkers, and targeted therapeutics can support differentiated development programs and strategic relevance to potential partners.
Prior Positive Cash GenerationThe 2024 results demonstrate that Genfit has previously converted operations into positive cash flow and earnings, rather than relying exclusively on external funding. Although performance has been inconsistent, this history indicates potential operating leverage if revenue and partnerships remain supportive.
Bears Say
Large Operating LossesThe return to large operating and net losses shows that recent revenue growth has not translated into durable profitability. This earnings volatility makes future results more dependent on pipeline milestones, transactions, or financing and reduces confidence in near-term earnings quality.
Renewed Cash BurnNegative operating and free cash flow indicate that the business is again consuming cash while developing its programs. The broader history of several years with sizable negative cash flow suggests that funding needs may persist and could constrain investment or strategic flexibility.
Balance-Sheet StressHigher debt combined with negative shareholders’ equity materially weakens Genfit’s financial resilience. This reduces balance-sheet flexibility if losses continue, increases dependence on successful business development or financing actions, and makes sustaining development spending more challenging.
Genfit News
GNFT FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was €3.05 and its highest was €15.48 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is €519.94M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Sep 29, 2026 which is in 4 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Apr 02, 2026. The company reported -€1.525 earnings per share for the quarter, missing the consensus estimate of -€0.03 by -€1.495.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -0.16.
How many shares outstanding does Genfit SA have?
Genfit SA has 50,099,620 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of -€1.525 in its last earnings report, missing expectations of -€0.03. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in FR:GNFT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genfit SA
Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibranor, which is progressing through Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). The firm is additionally engaged in advancing the NIS4 technology, designed for the accurate diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Other investigational treatments comprise GNS561, currently in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation for acute-on-chronic liver failure. Genfit has established key partnerships, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a molecular diagnostic test leveraging blood samples. Furthermore, it collaborates with Genoscience Pharma on the development and market launch of the experimental CCA therapy, GNS561. Established in 1999, Genfit S.A. maintains its headquarters in Loos, France.
GNFT Stock 12 Month Forecast
Average Price Target
€15.00
▲(4.90% Upside)